Last reviewed · How we verify
Botox Inj
Botox (botulinum toxin type A) blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
Botox (botulinum toxin type A) blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Botox Inj |
|---|---|
| Sponsor | Huons Co., Ltd. |
| Drug class | Botulinum toxin |
| Target | SNARE complex (synaptosome-associated protein) |
| Modality | Biologic |
| Therapeutic area | Neurology, Dermatology, Aesthetics |
| Phase | Phase 3 |
Mechanism of action
Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle fusion and release at motor nerve terminals. This results in temporary flaccid paralysis of injected muscles, lasting 3-4 months before neuromuscular junction recovery. The effect is localized to the injection site and reversible.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Chronic migraine
- Overactive bladder
- Hyperhidrosis
- Glabellar lines and facial wrinkles (cosmetic)
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Eyelid ptosis
- Dry mouth
- Flu-like symptoms
Key clinical trials
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- Botulinum Toxin Injection in the UES for R-CPD (PHASE4)
- Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis (PHASE2)
- Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines (PHASE3)
- Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure (NA)
- The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder (PHASE3)
- To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines (PHASE3)
- Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botox Inj CI brief — competitive landscape report
- Botox Inj updates RSS · CI watch RSS
- Huons Co., Ltd. portfolio CI